Home / News /

Caixa Innvierte BioMed II

Caixa Capital Risc leads sale of Sanifit Therapeutics to Vifor Pharma with upfront payment of €205M
24.11.2021 - Caixa Innvierte BioMed II, Life Sciences

• Largest acquisition in history of Spanish biotechnology sector and largest operation to date for Caixa Capital Risc
• Holding 20% of the capital, Caixa Capital Risc is Sanifit’s biggest stakeholder and has supported company since 2006, participating in all financing rounds for a total investment of over €23M

| Read more |

Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest
09.10.2020 - Caixa Innvierte BioMed II, Life Sciences

• Medlumics develops a unique real-time, photonically guided radiofrequency (RF) irrigated ablation catheter to improve the treatment of Atrial Fibrillation
• The proceeds from the Series E financing will be used to complete the preclinical development and obtain first in human data
•Medlumics strong investor syndicate includes Asabys Partners, VI Partners, Andera Partners, Caixa Capital Risc, Innogest Capital and CDTI Innvierte

| Read more |

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
08.10.2020 - Caixa Innvierte BioMed II, Life Sciences

• Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition
• Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales

| Read more |

Caixa Capital Risc is leading the largest operation in the biotech sector in Spain, with a €55 million financing round in Sanifit
26.06.2019 - Caixa Capital BioMed, Caixa Innvierte BioMed II, Life Sciences

• The financing ends with a loan capitalisation of €17 million, which brings the total of the operation to 72.2 million.
• It will speed up research into SNF472, a drug designed to treat a rare disease known as calciphylaxis.
• Two new investors are joining the company: Columbus Venture Partners and Alta Life Sciences.

| Read more |

Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary
12.03.2019 - Caixa Innvierte BioMed II, Life Sciences

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has appointed Mr. Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.

| Read more |
Older »